RKV Rakovina Therapeutics Inc.
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems. It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells. The company is also involved in the development of kt-5000 series of brain-penetrant dual ATRmTOR inhibitor drug candidates. It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies. Additionally, Rakovina Therapeutics Inc. has a strategic collaboration with Celvion Therapeutics to identify novel precision medicine strategies. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Rakovina Therapeutics (CVE: RKV)
›
Rakovina Therapeutics (CVE: RKV) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 0.1550 CAD on 19 November 2026, down 38.0% over 52 weeks. Its 52-week range is 0.0850 CAD to 0.3200 CAD: the price is 51.6% below the high and 82.4% above the low.
Its market capitalisation is 3.78M CAD.
Rakovina Therapeutics reports an operating margin of 0.0%.
Its debt exceeds its cash by 3.46M CAD, a debt-to-equity ratio of 18.58. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.2500 CAD is 61.3% above the current price. The next earnings report is expected on 26 November 2026.